• +1-646-491-9876
    • +91-20-67278686

    Search

    Cerebral Palsy - Pipeline Review, H1 2017

    Cerebral Palsy - Pipeline Review, H1 2017

    • Report Code ID: RW0001689376
    • Category Healthcare
    • No. of Pages 52
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Cerebral Palsy - Pipeline Review, H1 2017, provides an overview of the Cerebral Palsy (Central Nervous System) pipeline landscape.

    Cerebral palsy is a group of disorders that can involve brain and nervous system functions, such as movement, learning, hearing, seeing, and thinking. Symptoms include muscles that are very tight and do not stretch, abnormal walk (gait), arms tucked in toward the sides, knees crossed or touching, legs make scissors movements, walk on the toes, speech problems (dysarthria), hearing or vision problems and pain. Treatment includes anticonvulsants and muscle relaxants.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Cerebral Palsy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cerebral Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Cerebral Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cerebral Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 7 and 1 respectively.

    Cerebral Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Cerebral Palsy (Central Nervous System).
    - The pipeline guide reviews pipeline therapeutics for Cerebral Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Cerebral Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Cerebral Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Cerebral Palsy (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Cerebral Palsy (Central Nervous System).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Cerebral Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Cerebral Palsy - Overview
    Cerebral Palsy - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Cerebral Palsy - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Cerebral Palsy - Companies Involved in Therapeutics Development
    Allergan Plc
    Cell Cure Neurosciences Ltd
    Cellular Biomedicine Group Inc
    CHA Bio & Diostech Co Ltd
    CytoDel LLC
    GW Pharmaceuticals Plc
    Medy-Tox Inc
    Meridigen Biotech Co Ltd
    Neuralstem Inc
    Cerebral Palsy - Drug Profiles
    botulinum toxin next generation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cyto-012 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nabiximols - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NeurArrest - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NSI-566 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    onabotulinumtoxinA - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OP-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Cerebral Palsy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Cerebral Palsy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Cerebral Palsy and Systemic Lupus Erythematosus - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cerebral Palsy - Dormant Projects
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Cerebral Palsy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Cerebral Palsy - Pipeline by Allergan Plc, H1 2017
    Cerebral Palsy - Pipeline by Cell Cure Neurosciences Ltd, H1 2017
    Cerebral Palsy - Pipeline by Cellular Biomedicine Group Inc, H1 2017
    Cerebral Palsy - Pipeline by CHA Bio & Diostech Co Ltd, H1 2017
    Cerebral Palsy - Pipeline by CytoDel LLC, H1 2017
    Cerebral Palsy - Pipeline by GW Pharmaceuticals Plc, H1 2017
    Cerebral Palsy - Pipeline by Medy-Tox Inc, H1 2017
    Cerebral Palsy - Pipeline by Meridigen Biotech Co Ltd, H1 2017
    Cerebral Palsy - Pipeline by Neuralstem Inc, H1 2017
    Cerebral Palsy - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Cerebral Palsy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Allergan Plc
    Cell Cure Neurosciences Ltd
    Cellular Biomedicine Group Inc
    CHA Bio & Diostech Co Ltd
    CytoDel LLC
    GW Pharmaceuticals Plc
    Medy-Tox Inc
    Meridigen Biotech Co Ltd
    Neuralstem Inc

    Request for Sample

    Report Url http://www.reportsweb.com//cerebral-palsy-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//cerebral-palsy-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//cerebral-palsy-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments